Spiro Medical Raises $67 Million to Create Innovative Asthma Treatment Technology#USA#Neuromodulation#Irvine,_California#Asthma_Treatment#Spiro_Medical
Spiro Medical Raises $67 Million to Create Innovative Asthma Treatment Technology
Spiro Medical has successfully secured $67 million in Series A funding to develop a groundbreaking Pulmonary Neuromodulation System for asthma treatment, promising better outcomes for millions.
third-news.com
January 7, 2026 at 1:23 PM
Spiro Medical Raises $67 Million to Create Innovative Asthma Treatment Technology#USA#Neuromodulation#Irvine,_California#Asthma_Treatment#Spiro_Medical
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, Addressing Severe Asthma with AI Innovation#USA#Somerville#GenerateBiomedicines#Asthma_Treatment#GB-0895
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, Addressing Severe Asthma with AI Innovation
Generate Biomedicines has announced two global Phase 3 clinical trials for GB-0895, a long-acting anti-TSLP antibody designed for severe asthma treatment, engineered with AI technology.
third-news.com
December 1, 2025 at 11:20 AM
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, Addressing Severe Asthma with AI Innovation#USA#Somerville#GenerateBiomedicines#Asthma_Treatment#GB-0895
GenerateBiomedicines Launches Global Phase-3 Studies for GB-0895, an AI-Engineered Antibody Targeting Severe Asthma#USA#Somerville#GenerateBiomedicines#Asthma_Treatment#GB-0895
GenerateBiomedicines Launches Global Phase-3 Studies for GB-0895, an AI-Engineered Antibody Targeting Severe Asthma
Explore the groundbreaking Phase-3 trials initiated by GenerateBiomedicines for GB-0895, an AI-designed antibody aimed at treating severe asthma.
third-news.com
December 1, 2025 at 11:19 AM
GenerateBiomedicines Launches Global Phase-3 Studies for GB-0895, an AI-Engineered Antibody Targeting Severe Asthma#USA#Somerville#GenerateBiomedicines#Asthma_Treatment#GB-0895
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895 to Combat Severe Asthma#USA#Somerville#Clinical_Trials#Asthma_Treatment#GB-0895
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895 to Combat Severe Asthma
Generate Biomedicines unveils plans for two global Phase 3 trials assessing GB-0895 treatment for severe asthma, showcasing AI innovation in healthcare.
third-news.com
December 1, 2025 at 11:19 AM
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895 to Combat Severe Asthma#USA#Somerville#Clinical_Trials#Asthma_Treatment#GB-0895
Significant Growth Expected in Pulmonary Drug Delivery Market by 2031#USA#New_York#Pulmonary_Drug_Delivery#Asthma_Treatment#COPD_Solutions
Significant Growth Expected in Pulmonary Drug Delivery Market by 2031
The global pulmonary drug delivery market is projected to reach $73.14 billion by 2031, driven by rising chronic respiratory conditions and technological advancements.
third-news.com
June 24, 2025 at 3:52 PM
Significant Growth Expected in Pulmonary Drug Delivery Market by 2031#USA#New_York#Pulmonary_Drug_Delivery#Asthma_Treatment#COPD_Solutions